At the core of this transaction is a differentiated bispecific antibody targeting both DLL4 and VEGF-A, which inhibits both DLL4-mediated Notch signaling and VEGF signaling, which has been renamed CTX ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback